EXACT SCIENCES CORP (EXAS)
US30063P1057 - Common Stock
We assign a fundamental rating of 3 out of 10 to EXAS. EXAS was compared to 602 industry peers in the Biotechnology industry. EXAS has a bad profitability rating. Also its financial health evaluation is rather negative. EXAS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
EXAS had negative earnings in the past year.
In the past year EXAS had a positive cash flow from operations.
EXAS had negative earnings in each of the past 5 years.
EXAS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
EXAS's Return On Assets of -4.39% is amongst the best of the industry. EXAS outperforms 91.47% of its industry peers.
Looking at the Return On Equity, with a value of -9.04%, EXAS belongs to the top of the industry, outperforming 90.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.39% | ||
| ROE | -9.04% | ||
| ROIC | N/A |
ROA(3y)-11.88%
ROA(5y)-10.64%
ROE(3y)-24.97%
ROE(5y)-21.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EXAS's Gross Margin of 73.83% is amongst the best of the industry. EXAS outperforms 83.95% of its industry peers.
In the last couple of years the Gross Margin of EXAS has remained more or less at the same level.
EXAS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y0.53%
2. Health
2.1 Basic Checks
EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EXAS has more shares outstanding
Compared to 5 years ago, EXAS has more shares outstanding
The debt/assets ratio for EXAS is higher compared to a year ago.
2.2 Solvency
EXAS has an Altman-Z score of 1.72. This is a bad value and indicates that EXAS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EXAS (1.72) is better than 69.23% of its industry peers.
EXAS has a Debt/Equity ratio of 0.74. This is a neutral value indicating EXAS is somewhat dependend on debt financing.
EXAS has a Debt to Equity ratio of 0.74. This is in the lower half of the industry: EXAS underperforms 77.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.72 |
ROIC/WACCN/A
WACC10.25%
2.3 Liquidity
EXAS has a Current Ratio of 2.41. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
EXAS has a Current ratio of 2.41. This is in the lower half of the industry: EXAS underperforms 75.75% of its industry peers.
EXAS has a Quick Ratio of 2.13. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
EXAS's Quick ratio of 2.13 is on the low side compared to the rest of the industry. EXAS is outperformed by 76.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.13 |
3. Growth
3.1 Past
EXAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.15%, which is quite impressive.
EXAS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.99%.
EXAS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.94% yearly.
EPS 1Y (TTM)60.15%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q100%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y33.49%
Revenue growth 5Y50.94%
Revenue growth Q2Q20.11%
3.2 Future
EXAS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.65% yearly.
EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.53% yearly.
EPS Next Y45.14%
EPS Next 2Y29.29%
EPS Next 3Y25.87%
EPS Next 5Y19.65%
Revenue Next Year19.84%
Revenue Next 2Y17.07%
Revenue Next 3Y16.27%
Revenue Next 5Y14.53%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EXAS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EXAS's earnings are expected to grow with 25.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.29%
EPS Next 3Y25.87%
5. Dividend
5.1 Amount
EXAS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EXACT SCIENCES CORP
NASDAQ:EXAS (12/1/2023, 7:00:02 PM)
After market: 67.01 -0.02 (-0.03%)67.03
+3.03 (+4.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-01 2023-11-01/amc
Earnings (Next)02-19 2024-02-19/amc
Inst Owners88.39%
Inst Owner Change-1.3%
Ins Owners1.58%
Ins Owner Change-0.53%
Market Cap12.11B
Analysts85.38
Price Target108.5 (61.87%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)56.71%
Min EPS beat(2)13.42%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)43.62%
Min EPS beat(4)13.42%
Max EPS beat(4)100%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-0.13%
Max Revenue beat(2)1.63%
Revenue beat(4)3
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-0.13%
Max Revenue beat(4)8.69%
PT rev (1m)-3.94%
PT rev (3m)2.16%
EPS NQ rev (1m)2.35%
EPS NQ rev (3m)1.82%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.8%
Revenue NQ rev (1m)1.16%
Revenue NQ rev (3m)1.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.03 | ||
| P/FCF | N/A | ||
| P/OCF | 87.38 | ||
| P/B | 3.88 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.59
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)0.77
OCFY1.14%
SpS13.32
BVpS17.28
TBVpS-6.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.39% | ||
| ROE | -9.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.83% | ||
| FCFM | N/A |
ROA(3y)-11.88%
ROA(5y)-10.64%
ROE(3y)-24.97%
ROE(5y)-21.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y0.53%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 80.3% | ||
| Cap/Sales | 6.74% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.13 | ||
| Altman-Z | 1.72 |
F-Score5
WACC10.25%
ROIC/WACCN/A
Cap/Depr(3y)169.16%
Cap/Depr(5y)301.34%
Cap/Sales(3y)17.73%
Cap/Sales(5y)21.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y (TTM)60.15%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q100%
EPS Next Y45.14%
EPS Next 2Y29.29%
EPS Next 3Y25.87%
EPS Next 5Y19.65%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y33.49%
Revenue growth 5Y50.94%
Revenue growth Q2Q20.11%
Revenue Next Year19.84%
Revenue Next 2Y17.07%
Revenue Next 3Y16.27%
Revenue Next 5Y14.53%
EBIT growth 1Y56.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.68%
EBIT Next 3Y41.97%
EBIT Next 5Y27.86%
FCF growth 1Y95.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y311.28%
OCF growth 3YN/A
OCF growth 5YN/A